Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus

Journal of Clinical Pharmacology

Volumn 41, Issue 3, 2001, Pages 268-276

  Jain, Ashok ^b   Venkataramanan, Raman ^a   Hamad, Imad S ^b   Zuckerman, Sheila ^b   Zhang, Shimin ^b   Lever, Jackie ^a   Warty, Vijay S ^b   Fung, John J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MALE; STEADY STATE; TIME;

ADULT; AGED; AREA UNDER CURVE; BILE; BILIRUBIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GLUCURONATES; GLUCURONIDES; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; SERUM ALBUMIN; TACROLIMUS; TIME FACTORS;

EID: 0035123682     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010087     Document Type: Article

References (30)

1. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443
2. RS-61443 studies: Review and proposal
3. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis
4. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
5. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
6. The Pittsburgh randomized trial of tacrolimus versus cyclosporine for liver transplantation
7. Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression
8. Randomized trialomania? The multicentre liver transplant trials
9. Randomized trial comparing tacrolimus (FK 506) and cyclosporine in prevention of liver allograft rejection
10. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation
11. Manual and automated (robotic) high performance liquid chromatographic methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma
12. A whole blood FK506 assay for the IMx analyzer
13. Pharmacokinetics of oral 2-(4-morpholino) ethyl ester of mycophenolic acid (EE-MA) in liver transplant patients
14. Pharmacokinetics of oral mycophenolate mofetil in liver transplant patients
15. Pharmacokinetics of intravenous mycophenolate mofetil in liver transplant patients
16. RS-61443-A phase I clinical trial and pilot rescue study
17. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review
18. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function
19. Unexpected augmentation of MMF pharmacokinetics in renal transplant patients receiving Prograf® and Cellcept® in combination therapy and analogous in vitro findings
20. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure
21. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function
22. Pharmacokinetic-pharmacodynamic relationship for mycophenolic acid in renal transplant patients
23. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients
24. Pharmacokinetics of mycophenolic acid (MPA) and determination of MPA free fraction in pediatric and adult renal transplant recipients
25. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
26. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic degrees of hepatic oxidative impairment
27. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single dose oral and intravenous administration
28. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics